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Slower Uncoating Is Associated with Impaired Replicative
Capability of Simian-Tropic HIV-1
Ken Kono1¤☯, Eri Takeda1☯, Hiromi Tsutsui1, Ayumu Kuroishi1, Amy E. Hulme2, Thomas J. Hope2, Emi E.
Nakayama1, Tatsuo Shioda1*
1 Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan, 2 Department of Cell and Molecular Biology,
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America

Abstract
Human immunodeficiency virus type 1 (HIV-1) productively infects only humans and chimpanzees, but not Old World
monkeys, such as rhesus and cynomolgus (CM) monkeys. To establish a monkey model of HIV-1/AIDS, several
HIV-1 derivatives have been constructed. We previously generated a simian-tropic HIV-1 that replicates efficiently in
CM cells. This virus encodes a capsid protein (CA) with SIVmac239-derived loops between α-helices 4 and 5 (L4/5)
and between α-helices 6 and 7 (L6/7), along with the entire vif from SIVmac239 (NL-4/5S6/7SvifS). These
SIVmac239-derived sequences were expected to protect the virus from HIV-1 restriction factors in monkey cells.
However, the replicative capability of NL-4/5S6/7SvifS in human cells was severely impaired. By long-term cultivation
of human CEM-SS cells infected with NL-4/5S6/7SvifS, we succeeded in partially rescuing the impaired replicative
capability of the virus in human cells. This adapted virus encoded a G-to-E substitution at the 116th position of the CA
(NL-4/5SG116E6/7SvifS). In the work described here, we explored the mechanism by which the replicative capability
of NL-4/5S6/7SvifS was impaired in human cells. Quantitative analysis (by real-time PCR) of viral DNA synthesis
from infected cells revealed that NL-4/5S6/7SvifS had a major defect in nuclear entry. Mutations in CA are known to
affect viral core stability and result in deleterious effects in HIV-1 infection; therefore, we measured the kinetics of
uncoating of these viruses. The uncoating of NL-4/5S6/7SvifS was significantly slower than that of wild type HIV-1
(WT), whereas the uncoating of NL-4/5SG116E6/7SvifS was similar to that of WT. Our results suggested that the
lower replicative capability of NL-4/5S6/7SvifS in human cells was, at least in part, due to the slower uncoating of this
virus.
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Introduction

PIC migrates into the nucleus, where the viral DNA integrates
into the chromosomal DNA of the target cell.
HIV-1 uncoating was thought to occur immediately following
viral fusion, as CA was undetectable in RT complexes isolated
from infected cells [1–3]. Thus, CA was thought to have only a
minor role in HIV-1 infection. However, subsequent reports
indicated that mutations in CA decreased HIV-1 infectivity.
Most of these CA mutant viruses displayed decreased levels of
RT products [4–10]. On the other hand, the mutant virus
Q63/67A, which encodes two Gln-to-Ala substitutions in CA,
exhibited a defect in nuclear entry [4,11,12]. Changes in core
stability caused by some of these CA mutations seem to affect
uncoating kinetics, which may result in impaired RT or nuclear

HIV-1 infection begins with the interaction and fusion of viral
and cellular membranes. After fusion, a conical core, consisting
of the two viral genomic RNAs and several viral proteins, is
released into the cytoplasm of the target cell. The major
component of the core is the viral capsid protein (CA). In the
cytoplasm, CA eventually dissociates from the viral complex in
a process termed uncoating. During this time, reverse
transcription (RT) of the viral genomes occurs. The resultant
double-stranded DNA associates with viral and cellular
proteins, constituting the pre-integration complex (PIC). The
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entry. Thus, timely uncoating was thought to be important for
efficient HIV-1 infection. In agreement with this idea, anti-HIV
factors TRIM5α and TRIMCyp were shown to bind viral core
and accelerate uncoating, thus abrogating productive RT
[13–17]. This observation suggests that the core persists as a
defined structure for a certain period of time after fusion.
Intriguingly, Yamashita et al. showed that CA is important for
HIV-1 infection of non-dividing cells [11,18]. In addition, the
transportin-SR2 (or TNPO3) -dependence of HIV-1 nuclear
entry has been mapped to the HIV-1 CA [19,20]. These results
also suggest a functional link between the HIV-1 CA and
nuclear entry.
We previously generated simian-tropic HIV-1 that replicates
efficiently in cynomolgus monkey (CM) cells [21]. This virus
encodes a CA with SIVmac239-derived loops between αhelices 4 and 5 (L4/5) and between α-helices 6 and 7 (L6/7),
along with the entire SIVmac239 vif. These SIVmac239-derived
sequences allow HIV-1 to escape from restriction factors in
monkey cells, including cyclophilin A (CypA), TRIM5α, and
ApoB mRNA editing catalytic subunit (APOBEC) 3G. However,
the replicative capability of this virus (NL-4/5S6/7SvifS) in
human cells was severely impaired. By long-term cultivation of
human CEM-SS cells infected with NL-4/5S6/7SvifS, we
succeeded in partially rescuing the replicative capability of this
virus in human cells [22]. This adapted virus encoded a G-to-E
substitution
at
the
116th
position
of
the
CA
(NL-4/5SG116E6/7SvifS). Interestingly, this G116E mutation
also occurred after adaptation in rhesus monkey cells [23].
In the work presented here, we examined the mechanism by
which the replicative capability of NL-4/5S6/7SvifS was
severely impaired in human cells.

Program), the BssHII to ApaI fragment (corresponding to the
majority of the gag gene) was replaced with the corresponding
fragment of NL-4/5S6/7SvifS or NL-4/5SG116E6/7SvifS. Viral
titers were measured with the RETROtek antigen ELISA kit
(ZeptoMetrix, Buffalo, NY).

Viral infections
CEM-SS cells (2 x 105 per reaction) were infected with HIV-1
derivatives at titers equivalent to 20 ng of p24 per reaction.
Culture supernatants were collected periodically, and p24
levels were measured using an ELISA kit.

Real-time PCR analysis
CEM-SS cells (1 x 106 per reaction) were infected with
DNase I-pretreated HIV-1 derivatives at titers equivalent to 80
ng of p24 per reaction. DNase I pretreatment consisted of
incubation with DNase I (20 units/ml in 10 mM MgCl2) for 30
min at room temperature. After 2 hr on ice, infected cells were
washed with PBS, resuspended in medium, and returned to
37° C until harvesting at the indicated time point post-infection.
Genomic DNA was extracted by using the QIAamp DNA Blood
Mini kit (Qiagen). After digestion with 1 unit/μl DpnI for 4 hr at
37° C, 30 ng of DNA was analyzed for U5/gag, 2-LTR, and AluHIV by real-time PCR using published primers and TaqMan
probes [26,27] in an Applied Biosystems 7500 Real-Time PCR
System.

In situ uncoating assay
The in situ uncoating assay was conducted as previously
described [11,28]. Briefly, the labeled virus was generated by
cotransfecting 9 µg NL-Nh CA mutant proviral plasmid, 4 µg
S15-dTomato-expressing plasmid, 4 µg vesicular stomatitis
virus G protein (VSV-G)-expressing plasmid, and 1 µg GFPVpr-expressing plasmid into 10-cm plates of 293T cells using
PEI. HeLa cells were spinoculated with the labeled virus for 2
hr at 16° C in the presence or absence of bafilomycin A (BafA)
(Sigma). Virus-containing supernatant then was removed and
replaced with 37° C medium in the presence or absence of
BafA, shifted to 37° C, and fixed with 3.7% formaldehyde
(Polysciences) in 0.1M PIPES buffer (pH 6.8) at the indicated
time point post-infection. The fixed HeLa cells were
permeabilized with blocking solution (0.1 M PIPES [pH 6.8],
10% normal donkey serum [Jackson ImmunoResearch
Laboratories], 0.01% Triton X-100, 0.01% NaN3) for 5 min at
room temperature, stained with anti-p24 mAb AG3.0 (NIH AIDS
Research and Reference Reagent Program) in blocking
solution without Triton X-100 for 1 hr at room temperature for
primary staining, and secondarily stained with labeled Cy5
donkey anti-mouse antibodies (Jackson ImmunoResearch
Laboratories) for 30 min at room temperature. Images were
collected and deconvolved with a Deltavision microscope and
software (Applied Precision). Following deconvolution, images
were blinded for identity to remove bias during counting. The
number of GFP-positive virions was assessed at each time
point, and each virion was individually inspected for punctate
dTomato fluorescent signal and p24 Cy-5 signal.

Materials and Methods
Cells
The human kidney adherent 293T cells and the human
cervical cancer HeLa cells were cultured in Dulbecco’s
modified Eagle medium supplemented with 10% heatinactivated fetal bovine serum (FBS). Cells of the human T cell
line CEM-SS were maintained in RPMI 1640 medium
supplemented with 10% FBS.

Virus propagation
Virus stocks were prepared by transfection of 293T cells with
HIV-1 derivatives described previously [21,22,24] using
polyethylenimine
(PEI)
(molecular
weight,
25,000;
Polysciences). As shown in Figure 1A, NL-vifS possesses the
entire vif of SIVmac239 in the background of HIV-1 NL4-3 (NLSVR in reference [24]). NL-4/5S6/7SvifS encodes CA with the
SIVmac239-derived L4/5 and L6/7 in the background of NL-vifS
[21]. NL-4/5SG116E6/7SvifS encodes a CA with an additional
G-to-E substitution at the 116th position, in the background of
NL-4/5S6/7SvifS [22]. NL-Nh is a mutant of the NL4-3 proviral
clone in which an NheI restriction enzyme cleavage site was
blunted and re-ligated, introducing frame-shift mutations in the
env gene [25]. For NL-Nh, GFP-expressing NL4-3-derived
HIV-1 proviral clone MSMnG [25], and luciferase-expressing
NL4-3-Luc-R-E- (NIH AIDS Research and Reference Reagent
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Figure 1. Structure of the simian-tropic HIV-1 clones and the replication properties in human cells. (A) White bars denote
HIV-1 (NL4-3) and gray bars SIVmac239 sequences. (B) Equal amounts of NL-vifS (black diamonds), NL-4/5SvifS (white circles),
NL-4/5S6/7SvifS (white squares), and NL-4/5SG116E6/7SvifS (gray triangles) were inoculated into human CEM-SS cells, and
culture supernatants were collected periodically. p24 antigen levels were measured by ELISA. Error bars reflect actual fluctuations
of duplicate infections.
doi: 10.1371/journal.pone.0072531.g001
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Statistical analysis
Differences in luciferase activities, amounts of late RT
products, and uncoating kinetics were evaluated with unpaired
t tests.

Results
The replicative capability of NL-4/5S6/7SvifS was
impaired in human cells, while that of
NL-4/5SG116E6/7SvifS was partially rescued by a
single amino acid mutation in CA
Several HIV-1 derivatives have been constructed to establish
a monkey model of HIV-1/AIDS (Figure 1A). NL-4/5SvifS could
replicate in CM cells [24]. Introduction into NL-4/5SvifS of
SIVmac239 L6/7, which is a determinant of HIV type 2 (HIV-2)
CM TRIM5α sensitivity [29], improved viral growth in CM cells
[21]. However, the replicative capability of the resultant virus
(NL-4/5S6/7SvifS) in human cells was greatly attenuated. After
long-term cultivation of human CEM-SS cells infected with
NL-4/5S6/7SvifS, we succeeded in partially rescuing the
impaired replicative capability of the virus [22]. This adapted
virus (NL-4/5SG116E6/7SvifS) encoded a G-to-E substitution
at the 116th position of NL4-3 CA sequence. Figure 1B shows
the replication of NL-vifS that possesses the entire vif of
SIVmac in the background of HIV-1, NL-4/5SvifS,
NL-4/5S6/7SvifS, and NL-4/5SG116E6/7SvifS in human CEMSS cells. Consistent with our previous report [22], the
replicative capability of NL-4/5S6/7SvifS was severely impaired
in human cells (Figure 1B). On the other hand, the replicative
capability of NL-4/5SG116E6/7SvifS was improved compared
with that of NL-4/5S6/7SvifS, and slightly better than that of
NL-4/5SvifS, even though replication did not reach the levels
seen with NL-vifS.
We then inoculated CEM-SS cells with VSV-G-pseudotyped
luciferase- expressing HIV-1 vector encoding wild type (WT),
4/5S6/7S, or 4/5SG116E6/7S CA. As shown in Figure 2A,
infectivity was significantly reduced by the 4/5S6/7S mutation
(p<0.0001), and infectivity was restored by addition of the
G116E mutation to 4/5S6/7S (p=0.0004). Similar results were
obtained when we used a VSV-G-pseudotyped GFPexpressing version of the HIV-1 vector (Figure 2B). These
results clearly indicated that the different replicative capability
of the viruses was due mainly to effects at the early stage of
viral replication.

Figure 2. Single round infection assays. (A) 3X105 CEMSS cells were infected with viral titers equivalent to 5 ng of p24
of VSV-G-pseudotyped luciferase-expressing viruses with
NL4-3 CA (NL-Luc), 4/5S6/7S CA (NL-4/5S6/7S-Luc), or
4/5SG116E6/7S CA (NL-4/5SG116E6/7S-Luc). The luciferase
activity was measured at 48 hr after infection by a luminometer.
Error bars reflect the SD of triplicate infections. Presented data
are representative of two independent experiments using a
different set of molecular clones. (B) 3X105 CEM-SS cells were
infected with viral titers equivalent to 80 ng of p24 of VSV-Gpseudotyped GFP-expressing viruses with NL4-3 CA (NLGFP),
NL-4/5S6/7S
CA
(NL-4/5S6/7S-GFP),
or
NL-4/5SG116E6/7S CA (NL-4/5SG116E6/7S-GFP). The GFPpositive cells were counted at 24 hr after infection by a flow
cytometer. Error bars reflect the SD of triplicate infections.
Presented data are representative of two independent
experiments using a different set of molecular clones.

Levels of NL-4/5S6/7SvifS RT products were decreased
at 12 hours after infection
To determine which step of NL-4/5S6/7SvifS early infection
stage was impaired, we first measured RT products of
replication-competent viruses NL-vifS, NL-4/5S6/7SvifS, and
NL-4/5SG116E6/7SvifS in CEM-SS cells. At 12 hr after
infection, the amounts of U5/gag (late RT products) and 2-LTR
circles (a surrogate for nuclear entry) of NL-4/5S6/7SvifS were
69.4% (p=0.0270) and 38.6% (p=0.0003) of those of NL-vifS,
respectively (Figure 3A). These results suggested that
NL-4/5S6/7SvifS has defects in both RT and nuclear entry. On
the other hand, the amount of Alu-HIV (integrated viral DNA) of
NL-4/5S6/7SvifS was 38.2% (p=0.0029) that of NL-vifS, being

doi: 10.1371/journal.pone.0072531.g002
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comparable to that of 2-LTR circles. These results suggested
that NL-4/5S6/7SvifS has WT-like ability to integrate after
nuclear entry. In the case of NL-4/5SG116E6/7SvifS, the
amount of late RT, 2-LTR, and Alu-HIV were 67.5%
(p=0.0216), 38.4% (p=0.0005), and 38.5% (p=0.0052) of NLvifS,
respectively.
These
results
suggested
that
NL-4/5SG116E6/7SvifS also was impaired for RT and nuclear
entry. We failed to detect any significant recovery of late RT
(p=0.88), 2-LTR (p=0.98), or Alu-HIV (p=0.98) of
NL-4/5SG116E6/7SvifS by addition of the G116E mutation to
NL-4/5S6/7SvifS.
We then measured RT products during a 72-hr time course
(Figure 3B). The amount of late RT products of
NL-4/5S6/7SvifS and NL-4/5SG116E6/7SvifS were decreased
to similar extents at 24 hr after infection (Figure 3B upper
panel), likely because of degradation of unproductive products.
Supporting this idea, the levels of Alu-HIV, an outcome of
productive infection, continued to increase in cells infected with
these viruses (Figure 3B lower panel). On the other hand, the
level of late RT of NL-vifS at 24 hr after infection was almost
the same as that at 12 hr after infection. This persistence is
likely due to the balance between degradation of unproductive
RT products from the first round of infection and newly
generated RT products from the second-round infection by the
progeny viruses, since this experiment used replicationcompetent viruses. In the cases of NL-4/5S6/7SvifS and
NL-4/5SG116E6/7SvifS, the RT products from the secondround infection also would be impaired. Thus, these viruses
were not expected to overcome the degradation of
unproductive RT products of the initial infection. The difference
of late RT, 2-LTR, and Alu-HIV between NL-4/5S6/7SvifS and
NL-4/5SG116E6/7SvifS gradually expanded at 48 and 72 hr
after infection, presumably due to the effects of multiple rounds
of infection. This result was in good agreement with that of the
p24 production shown in Figure 1B.

products compared to NL-vifS at the respective time points.
Similar to NL-vifS, however, the late RT products of
NL-4/5SG116E6/7SvifS gradually increased until 12 hr after
infection. These findings also were unexpected and indicated
that the single G-to-E substitution (which at least partially
rescued the impaired replicative capability of NL-4/5S6/7SvifS
in human cells) also attenuated late RT at the earlier time
points. Therefore, the mechanism underlying decreased late
RT product levels of NL-4/5S6/7SvifS at 12 hr after infection
seemed
to
be
totally
different
from
that
of
NL-4/5SG116E6/7SvifS.
Next, we measured amounts of RT product of
aforementioned VSV-G-pseudotyped GFP-expressing HIV-1
vectors in a single-round infection assay to confirm the results
seen with replication-competent viruses. The absolute copy
numbers of RT products of GFP-expressing viruses were less
than those of replication-competent viruses, probably due to
increase of genome size by reporter gene insertion. However,
amounts of the late RT products of the virus encoding
4/5S6/7S CA at 8 hr after infection exceeded those of the virus
encoding NL4-3 CA (p=0.04, Figure 4B), as observed in
replication-competent viruses. At 16 hr after infection, the
amounts of the late RT products of the virus encoding
4/5S6/7S CA were less than those of the virus encoding NL4-3
CA (p=0.007, Figure 4B), consistent with the results of
replication-competent viruses. Furthermore, amounts of late RT
products of the virus encoding 4/5S116E6/7S CA were lower
than those of the virus encoding NL4-3 CA at 16 hr after
infection (p=0.009, Figure 4B). Thus, the results of replicationincompetent viruses clearly confirmed the results of replicationcompetent viruses. Similar results also were obtained when we
used VSV-G-pseudotyped NL-Nh versions of the viruses (data
not shown).

The levels of late RT product of NL-4/5S6/7SvifS were
increased at the earlier time points of infection

Several studies have reported that mutations in CA affected
viral core stability and resulted in deleterious effects on RT [4]
or nuclear entry [12]. To determine whether the CA mutations
in NL-4/5S6/7SvifS or NL-4/5SG116E6/7SvifS affect the core
stability, we performed an in situ uncoating assay according to
the method described previously [11,28]. For our experiment, a
replication-incompetent virus (NL-Nh), which carries a frameshift mutation in the env gene, was used as the wild type virus.
The CA of NL-Nh was replaced with that of NL-4/5S6/7SvifS or
NL-4/5SG116E6/7SvifS, since the virus had to be pseudotyped
with VSV-G. NL-Nh, NL-Nh mutant encoding 4/5S6/7S CA, and
NL-Nh mutant encoding 4/5SG116E6/7S CA were labeled with
GFP-Vpr, while the viral membrane was labeled with S15dTomato; the membrane label was expected to disappear after
productive fusion of the virion into the cytoplasm. To provide a
negative control reaction, bafilomycin A (BafA) was included to
block fusion of the virus and cellular membranes. This control
was used to confirm that unfused viral particles fail to undergo
uncoating. Infection was synchronized and at various times
after infection the cells were fixed and stained with an antibody
to p24 CA. The total number of complexes that entered the
cytoplasm (green spots that lost S15-dTomato) was counted,

The uncoating kinetics of NL-4/5S6/7S was slower than
that of the virus with the NL4-3 CA

To determine the mechanisms of the decreased RT
production of NL-4/5S6/7SvifS and NL-4/5SG116E6/7SvifS, we
analyzed RT at earlier time points after infection. Contrary to
our expectation, the amount of late RT products of
NL-4/5S6/7SvifS exceeded that of NL-vifS at 4 and 8 hr after
infection (Figure 4A). This result indicated that the kinetics of
RT product generation was faster for NL-4/5S6/7SvifS than for
NL-vifS, despite the fact that the 12-hr levels of late RT
products were lower with NL-4/5S6/7SvifS than with NL-vifS
(Figures 3A and 4A). The late RT production of
NL-4/5S6/7SvifS peaked at 8 hr after infection before
decreasing at 12 hr after infection. In contrast, late RT products
of NL-vifS gradually increased until 12 hr after infection. The
peak amount of late RT products with NL-4/5S6/7SvifS was
comparable to that with NL-vifS. Thus we conclude that
NL-4/5S6/7SvifS had a defect not in RT but in nuclear entry,
and that the synthesized viral cDNA that failed to enter the
nucleus was degraded.
In
a
sharp
contrast
to
NL-4/5S6/7SvifS,
NL-4/5SG116E6/7SvifS yielded reduced amounts of late RT
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Figure 3. Measurement of the reverse transcribed products of simian-tropic HIV-1 in human cells. (A) CEM-SS cells were
infected with NL-vifS, NL-4/5S6/7SvifS, or NL-4/5SG116E6/7SvifS, and DNA was extracted at 12 hr after infection and subjected to
real-time PCR assays using U5/gag primers for late reverse transcription (RT), 2-LTR primers for nuclear transported viral DNA, and
Alu-HIV primers for integrated DNA. Mean relative amounts of U5/gag, 2-LTR, and Alu-HIV products obtained from three
independent experiments (the amount in the NL-vifS sample at 12 hr after infection is set at 1) are indicated. Mean numbers of U5/
gag, 2-LTR, and Alu-HIV copies per 30 ng of total DNA of NL-vifS-infected cells were 39695, 187, and 2.17, respectively. Error bars
reflect the SD of the three independent experiments. (B) CEM-SS cells were infected with NL-vifS, NL-4/5S6/7SvifS, or
NL-4/5SG116E6/7SvifS, and DNA was extracted at 12, 24, 48, and 72 hr after infection and subjected to real-time PCR assays as
described above. The number of viral DNA (U5/gag and 2-LTR) copies per 30 ng of total DNA and relative amount of Alu-HIV
products (the amount in the NL-vifS sample at 12 hr after infection is set at 1) is indicated. Error bars reflect the SD of triplicate
values of real-time PCR. Presented data are representative of three independent experiments.
doi: 10.1371/journal.pone.0072531.g003
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Figure 5. In situ uncoating assay. HeLa cells were
spinoculated with VSV-G-pseudotyped, S15-dTomato, GFPVpr -labeled NL-Nh (WT; black diamonds), NL-Nh with
4/5S6/7S CA (NL-4/5S6/7S, white squares), or NL-Nh with
4/5SG116E6/7S CA (NL-4/5G116E6/7S, gray triangles) for 2 hr
at 16° C in the presence or absence of bafilomycin A (BafA).
Infection was synchronized by washing off inocula and
replacing with 37° C medium. At the indicated time postinfection, the cells were fixed, immunostained for p24 CA
(Cy-5), and imaged. The identity of the samples was blinded
before counting. GFP-positive puncta then were quantified and
individually examined for the presence of dTomato and Cy-5
(p24 CA) signals. The percentage of the total number of fused
(dTomato-) virions that stained for p24 CA over time following
fusion is shown. The 0-hr time point and BafA (+) samples
represent total number of GFP-positive virions that stained
positive for p24 CA. For BafA treatment, only data from the 4-hr
time points on 4/5S6/7S CA (NL-4/5S6/7S+Baf, a grey square),
or 4/5SG116E6/7S CA (NL-4/5G116E6/7S+Baf, a black
triangle) are shown. The results shown are means and SD from
three independent experiments. Actual numbers of counted
dots are provided in Table S1.

Figure 4. Measurement of the U5/gag (late RT products)
during a 12-hr time course. (A) NL-vifS (black diamonds),
NL-4/5S6/7SvifS (white squares), and NL-4/5SG116E6/7SvifS
(gray triangles) were inoculated into human CEM-SS cells.
Genomic DNA was extracted at the indicated time point postinfection and subjected to real-time PCR assays using U5/gag
primers. The number of U5/gag copies per 30 ng of total DNA
is indicated. Error bars reflect the SD of triplicate
measurements of real-time PCR. Presented data are
representative of two independent experiments. (B) VSV-Gpseudotyped GFP-expressing viruses with NL4-3 CA (NL-GFP,
black diamonds), 4/5S6/7S CA (NL-4/5S6/7S-GFP, white
squares), and 4/5SG116E6/7S CA (NL-4/5SG116E6/7S-GFP,
black triangles) were inoculated into human CEM-SS cells.
Real-time PCR assays using U5/gag primers were performed
as described above. Error bars reflect the SD of triplicate
infections. Presented data are representative of three
independent experiments.

doi: 10.1371/journal.pone.0072531.g005

of CA-positive particles that were not significantly different from
those seen with the virus encoding NL4-3 CA (p=0.18 and
p=0.08 for 1 and 2 hr, respectively). The differences between
4/5S6/7S and 4/5SG116E6/7S viruses at 1 and 2 hr after
infection were small but statistically significant (p=0.021 and
p=0.037 respectively). These results suggested that the
uncoating kinetics of NL-4/5S6/7SvifS was slower than that of
NL-vifS, while the uncoating kinetics of NL-4/5SG116E6/7SvifS
was similar to that of NL-vifS.

doi: 10.1371/journal.pone.0072531.g004

and the number of complexes that contained CA (coated) was
compared to the number of complexes that lost CA staining
(uncoated). The data was graphed at each time point as the %
of fused CA-positive (coated) cytoplasmic particles (Figure 5).
Actual numbers of counted dots are shown in Table S1. At 1
and 2 hr after infection, virus encoding 4/5S6/7S CA had a
higher percentage of CA-positive particles than did the virus
encoding NL4-3 CA; the difference was significant (p=0.018
and p=0.018 for 1 and 2 hr, respectively) at each time point. In
comparison, virus encoding 4/5SG116E6/7S CA had amounts

PLOS ONE | www.plosone.org

Discussion
We previously constructed a simian-tropic HIV-1
NL-4/5S6/7SvifS that can replicate well in CM cells [21,22].
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However, the replicative capability of this virus in human cells
was severely impaired. NL-4/5S6/7SvifS showed nearly normal
levels of Gag processing and human TRIM5α sensitivity similar
to that of NL4-3 [22]. In the present study, we showed that the
amount of RT products of NL-4/5S6/7SvifS was reduced
compared to those of NL-vifS at 12 hr after infection.
Surprisingly, however, the amount of the RT products of
NL-4/5S6/7SvifS at 4 and 8 hr after infection was elevated
compared to that of WT. Analysis of 2-LTR and integrated HIV
DNA suggested that NL-4/5S6/7SvifS had a defect in nuclear
entry
but
not
in
integration.
By
contrast,
NL-4/5SG116E6/7SvifS, which encodes a single G116E
substitution in CA, showed partial restoration of replicative
capability, even though the amount of the RT products was
apparently reduced. These results indicated that the G-to-E
substitution at the 116th position of CA impaired RT production
but restored the defect of NL-4/5S6/7SvifS in the subsequent
step.
Mutations in CA have been reported to affect viral core
stability, resulting in deleterious effects on RT [4,10] or nuclear
entry [12]. In the work described here, VSV-G-pseudotyped
virus with NL-4/5S6/7S CA showed slower uncoating kinetics.
Thus, it is possible that the hyper-stable core of
NL-4/5S6/7SvifS affects nuclear entry, resulting in lower
replicative capability in human cells. It remains unclear why the
hyper-stable core would be deleterious for nuclear entry. One
possible explanation is that the hyper-stable core masks viral
nuclear localization signals of matrix, integrase, or Vpr [30–32],
or masks a viral DNA structure, the central DNA flap, which is
known to be important for nuclear targeting [33–36]. Another
possibility is that host factors that are required for HIV-1 to
enter the nucleus, such as importin α/importin β heterodimer
[37–39], importin 7 [37,40,41], NUP153 [42], and TNPO3 [20],
are unable to access the viral particles at the proper time or
place. Although TNPO3 has been shown to bind HIV-1
integrase, Krishnan et al. recently showed that CA is the viral
factor that dictates TNPO3 dependency [43]. Thus it is also
possible that mutations in CA of NL-4/5S6/7SvifS affected the
interaction between CA and TNPO3.
It is possible that the core of each HIV-1 CA mutant has its
own optimal uncoating kinetics for RT production. For example,
a virus with Q63/67A mutations in CA previously has been
shown to uncoat more slowly than WT, but could synthesize
cDNA at a level comparable to that of WT during single-round
infection [4,11,12,44]. In the case of NL-4/5S6/7SvifS, the slow
uncoating may be optimal for its RT, since RT production by
this virus was faster than that by WT, even though the slower
uncoating might be deleterious for nuclear entry. If so, it is
reasonable to assume that the G-to-E substitution at the 116th
position of CA that reduced the core stability of
NL-4/5S6/7SvifS resulted in impaired RT. Further studies,
including evaluation of physical core stability and more precise
analysis of RT products, are necessary to substantiate this
hypothesis.
It is known that drug-resistant HIV-1 often acquires mutations
that have a negative effect on viral replicative capability
[45–50]. In addition, some of the resistant viruses acquire
secondary mutations that do not compensate directly for the
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negative effects caused by the primary mutations, but instead
improve another step, resulting in better replicative capability
[51,52]. Similarly, the G-to-E substitution at the 116th position of
CA may impair RT production but compensate for a defect of
NL-4/5S6/7SvifS in a subsequent step. In the present study,
however, we failed to resolve the step at which the G116E
substitution of CA compensates for a defect of
NL-4/5S6/7SvifS, since no significant improvement was
observed in the levels of 2-LTR circles (nuclear entry) nor HIVAlu (integration) of NL-4/5SG116E6/7S at 12 hr after infection
(Figure 3). The addition of the G116E mutation to
NL-4/5S6/7SvifS may change the affinity of viral core for
certain host factors and subsequently allow viral cDNA to be
integrated at chromosome positions that are preferable for
subsequent transcription. Alternatively, we might have failed (in
Figure 3) to detect very small recoveries of 2-LTR circles
and/or HIV-Alu levels, although these recoveries were sufficient
to be detected after amplification by viral transcription (in
Figure 2). Further studies would be required to elucidate the
precise mechanisms by which the G116E mutation at least
partially restored the impaired infectivity of NL-4/5S6/7SvifS.
We note that the uncoating process was completed within
4hr after infection (as shown in Figure 5), while the levels of the
late-RT products continued to increase through 8-12 hr (as
shown in Figures 3 and 4). Similar delay in accumulation of
late-RT product compared with uncoating kinetics was reported
previously [44]. Since a fluorescence-labeled antibody was
used to detect assembled CAs of the pre-uncoating cores in
the uncoating assay, it is likely that some cores undergoing
uncoating became undetectable in this assay but still continued
RT production. At present, the precise role of CA in nuclear
entry and integration of HIV-1 remains to be elucidated. Further
studies would be needed to determine the number of CA
molecules required for efficient nuclear entry and integration of
HIV-1 pre-integration complex.
It should be noted here that the amounts of p24 from culture
supernatants of 293T cells transfected with NL-4/5S6/7SvifS
and NL-4/5SG116E6/7SvifS plasmid constructs were
approximately 75% of those of NL-vifS (data not shown). These
results suggested that the viral assembly step also is impaired
in NL-4/5S6/7SvifS, and that the G-to-E substitution in
NL-4/5SG116E6/7SvifS fails to compensate for the mild defect
in assembly of NL-4/5S6/7SvifS. Therefore, defects in both
early and late viral replication steps may contribute to the
impaired replicative capabilities of NL-4/5S6/7SvifS and
NL-4/5SG116E6/7SvifS in human cells. It is also possible that
NL-4/5S6/7SvifS has defects in steps other than those
assessed in the present study.
In the study presented here, we showed that a simian-tropic
HIV-1, NL-4/5S6/7SvifS, exhibited both slower uncoating and a
defect in nuclear entry. On the other hand, the adapted virus
NL-4/5SG116E6/7SvifS showed recovered uncoating kinetics.
In addition to the Q63/67A mutant, 4/5S6/7S is the second
example showing the association of slower uncoating with a
disadvantage in nuclear entry. However, it is too early to
generalize from this conclusion, and further studies on various
other CA mutants would be required to elucidate the precise
role of uncoating kinetics in HIV-1 replication.
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Conclusions

Tadashi Miyamoto for helping with experiments, and Setsuko
Bandou and Noriko Teramoto for their assistance. pNL4-3-LucR-E- plasmid and AG3.0 antibody to p24CA were obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH. NL-Nh and MSMnG plasmid
were kind gifts from Dr. Jun-ichi Sakuragi.

Our results suggest that the lower replicative capability of
NL-4/5S6/7SvifS in human cells is due to the slower uncoating
of this virus.
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